Argatroban Plus R-tPA for Acute Ischemic Stroke
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 808 participants.
Also called NCT03740958
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 808 participants
- Registry
-
NCT03740958
-
- Other papers using this trial's data
- Circadian Rhythm and Efficacy of Argatroban in Ischemic Stroke with Alteplase: A Post Hoc Analysis of the ARAIS Trial
- Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03740958. Randomized; no masking; primary purpose treatment. Start 2018-12-21 (actual); primary completion 2022-01-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Argatroban Plus R-tPA for Acute Ischemic Stroke
- Condition
- Stroke
- Intervention (Drug)
- rt-PA
- Intervention (Drug)
- Argatroban
- Lead sponsor
- General Hospital of Shenyang Military Region
Record details
- Record id
cardio:ct-nct03740958- Content hash
c952bbd0d98659c3e0d848b1bcf5f3a0e91c13e78ebd93502d6c844cd41c9bd5